Immunovant Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Immunovant
IMVT Stock  USD 28.73  1.57  5.78%   
Immunovant financial statements provide useful quarterly and yearly information to potential Immunovant investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immunovant financial statements helps investors assess Immunovant's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immunovant's valuation are summarized below:
Market Capitalization
4.2 B
Earnings Share
(2.21)
There are currently one hundred twenty fundamental trends for Immunovant that can be evaluated and compared over time across competitors. All traders should confirm Immunovant's regular fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 1.4 B in 2024, whereas Market Cap is likely to drop slightly above 918.7 M in 2024.
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 34.8 M or Other Operating Expenses of 296.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.8 K. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
  
Check out the analysis of Immunovant Correlation against competitors.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Immunovant Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets699.7 M666.4 M187.4 M
Slightly volatile
Total Current Liabilities27.1 M48.6 M14.1 M
Slightly volatile
Accounts Payable5 M7.2 M3 M
Slightly volatile
Common Stock Shares Outstanding80.8 M138.1 M45.5 M
Slightly volatile
Total Liabilities27.7 M48.6 M14.3 M
Slightly volatile
Total Current Assets699.1 M665.8 M186.8 M
Slightly volatile
Short and Long Term Debt Total131.1 K138 K877.3 K
Slightly volatile
Other Current Liabilities24.7 M41.2 M10.7 M
Slightly volatile
Property Plant And Equipment Net565.2 K595 K589.8 K
Slightly volatile
Cash367.9 M635.4 M158.5 M
Slightly volatile
Non Current Assets Total565.2 K595 K654.1 K
Slightly volatile
Non Currrent Assets Other179.3 K282.9 K144.4 K
Slightly volatile
Cash And Short Term Investments367.9 M635.4 M158.5 M
Slightly volatile
Net Receivables4.8 M5.5 M3.7 M
Slightly volatile
Common Stock Total Equity8.9 K14.9 K4.4 K
Slightly volatile
Liabilities And Stockholders Equity386.8 M666.4 M166.7 M
Slightly volatile
Non Current Liabilities Total329.6 K347 K1.4 M
Pretty Stable
Capital Surpluse556.3 M1.1 B276.8 M
Slightly volatile
Other Current Assets13.1 M24.9 M5.6 M
Slightly volatile
Deferred Long Term Liabilities210.3 K221.4 K811.4 K
Slightly volatile
Net Invested Capital354.9 M617.8 M152.9 M
Slightly volatile
Short and Long Term Debt240 K270 K294 K
Slightly volatile
Capital Stock10 K14 K4.4 K
Slightly volatile
Short Term Debt262.2 K276 K740.3 K
Slightly volatile
Common Stock10 K14 K4.4 K
Slightly volatile
Property Plant Equipment216.3 K382.9 K134.3 K
Slightly volatile
Property Plant And Equipment Gross565.2 K595 K628.8 K
Slightly volatile
Non Current Liabilities Other40.2 K42.3 K1.7 M
Slightly volatile

Immunovant Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative34.8 M57.3 M17.8 M
Slightly volatile
Other Operating Expenses296.8 M282.7 M74.8 M
Slightly volatile
Research Development118.3 M212.9 M121.2 M
Very volatile
Total Operating Expenses150.5 M282.7 M137.7 M
Pretty Stable
Depreciation And Amortization219.4 K231 K268.4 K
Slightly volatile
Cost Of Revenue219.4 K231 K281 K
Slightly volatile
Reconciled Depreciation139.9 K231 K64.3 K
Slightly volatile
Non Recurring8 M9 M9.8 M
Slightly volatile
Selling And Marketing Expenses184.8 K207.9 K226.4 K
Slightly volatile

Immunovant Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation242.6 K231 K63.9 K
Slightly volatile
Total Cash From Financing Activities325 K472.4 M153.4 M
Pretty Stable
Change To Netincome39 M37.1 M12.6 M
Slightly volatile
Sale Purchase Of Stock23.8 K25 K43.8 M
Slightly volatile
Stock Based Compensation24.5 M41.1 M10.5 M
Slightly volatile
End Period Cash Flow367.8 M635.4 M158.3 M
Slightly volatile
Change To Inventory373.4 K685.4 K245.1 K
Slightly volatile
Begin Period Cash Flow303.2 M376.5 M116.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables454.4 K511.2 K556.7 K
Slightly volatile
Capex To Depreciation5.21.55842.1008
Slightly volatile
Payables Turnover0.03070.03230.113
Slightly volatile
Cash Per Share0.02264.60082.5147
Pretty Stable
Days Payables Outstanding8.5 K11.3 K15.6 K
Slightly volatile
Income Quality1.00.82610.8985
Slightly volatile
Net Debt To EBITDA9.0E-42.35291.6247
Pretty Stable
Current Ratio0.8513.69674.3825
Slightly volatile
Graham Number0.001113.74797.3466
Pretty Stable
Debt To Equity12.222.0E-41.6498
Slightly volatile
Capex Per Share0.00360.00260.0015
Slightly volatile
Interest Debt Per Share0.02090.0010.0639
Slightly volatile
Debt To Assets0.742.0E-40.1165
Slightly volatile
Days Of Payables Outstanding8.5 K11.3 K15.6 K
Slightly volatile
Ebt Per Ebit1.00.91531.0042
Pretty Stable
Total Debt To Capitalization0.922.0E-40.1432
Slightly volatile
Debt Equity Ratio12.222.0E-41.6498
Slightly volatile
Quick Ratio0.8513.69674.3825
Slightly volatile
Net Income Per E B T0.81.00220.9875
Slightly volatile
Cash Ratio0.8513.07127.665
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.01.00171.0011
Slightly volatile
Debt Ratio0.742.0E-40.1165
Slightly volatile

Immunovant Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap918.7 M1.7 B885.6 M
Slightly volatile
Enterprise Value1.4 B1.4 B749.3 M
Slightly volatile

Immunovant Fundamental Market Drivers

Cash And Short Term Investments635.4 M

Immunovant Upcoming Events

2nd of February 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Immunovant Financial Statements

Immunovant shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-24 M-22.8 M
Cost Of Revenue231 K219.4 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY